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1. Abbreviations 
AC 
  
Adenylate cyclase  
  Ang II 
  
Angiotensin II 
  ATPase 
  
Adenosinetriphosphatase 
 cAMP 
  
Cyclic adenosine monophosphate 
CaR 
  
Calcium-sensing receptors 
 CEC 
  
Chelerythrine chloride 
 DAG 
  
Diacylglycerol 
  ECD 
  
Extracellular domain 
  ECE 
  
Endothelin-converting enzyme  
 ET-1 
  
Endothelin-1 
  ETA 
  
Endothelin receptors type A 
 ETB 
  
Endothelin receptors type B 
 Gd 
  
Gadolinium 
  GPCR 
  
G protein-coupled receptors 
 I/R 
  
Ischemia-reperfusion  
 ICD 
  
Intracellular domain  
  IGF II 
  
Insulin-like growth factor II 
 IP3 
  
Inositol triphosphate  
 IP3R 
  
Inositol triphosphate receptor 
 MAPK 
  
Mitogen-activated protein kinase 
MLP 
  
Myocarial LIM protein  
 NO 
  
Nitric oxide 
  NOS 
  
Nitric oxide synthase  
 ODC 
  
Ornithine decarboxylase 
 PI4K 
  
Phosphatidylinositol 4-kinase 
 PKC 
  
Protein kinase C 
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PLB 
  
Phospholamban  
  PLC 
  
Phospholipase C 
  PTH 
  
Parathyroid hormone  
 PTHrP 
  
Parathyroid hormone-related protein 
RAMP 
  
Receptor activity-modifying protein  
RyR 
  
Ryanodine receptor 
  SERCA 
  
Sarco/endoplasmic reticulum Ca
2+
-ATPase 
SR 
  
Sarcoplasmic reticulum 
 TGF-β 
  
Transforming growth factor-β 
 TMD 
  
Transmembrane domain 
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2. Introduction 
2.1. Heart failure 
In developed countries, heart failure is the main reason of hospitalization 
of the people aged above 65 years and takes first place among factors, 
leading to death. These patients also suffer from side events, such as 
arrhythmia, tachycardia, oedema, dyspnea, and different violations in 
blood circulation. Many cardiovascular diseases lead to the heart failure 
development later on [Guha et al., 2013]. 
The definition of the heart failure by European society of Cardiology 
says: “Heart failure is a clinical syndrome in which patients have typical 
symptoms and signs resulting from an abnormality of cardiac structure 
and function” [McMurray et al., 2012]. Thus, heart failure is a state in 
which cardiac output is not able to cover body needs. Many reasons can 
lead to loss of heart muscle efficiency via its damage or overloading 
such as, - myocardial infarction, hypertension, diabetes, and 
amyloidosis. Patients with heart failure used to have reduced contraction 
force of ventricles. In normal healthy hearts, increased filling leads to an 
increased contraction force (Frank-Starling law of the heart) and this 
way enhances cardiac output. During heart failure, these mechanisms 
break down and ventricles overloaded with blood are not further able to 
increase required cardiac output. A reduced stroke volume can be a 
result of systolic or diastolic dysunction. Systolic heart failure is usually 
easier to recognize and diagnose. It is a failure of pump activity of the 
heart muscle and usually leads to an increased heart volume. Heart 
failure caused by diastolic dysfunction is more difficult to identify. It is 
9 
 
not always caused by heart hypertrophy and usually happens due to 
violation of relaxation phase.  
2.2. Cardiac hypertrophy 
Hypertension and hypertrophy are one of the events leading to the heart 
failure development [Mann et al., 2005]. Heart muscle hypertrophy is an 
adaptive response of the heart to pressure overload. Left ventricular 
hypertrophy is the most common event, nevertheless, enlargement also 
occurs in atria and right ventricle.  
Ventricular hypertrophy is known as an increase in the heart muscle 
mass. Two types of cardiac hypertrophy can be distinguished: healthy 
and pathological. Healthy cardiac hypertrophy is the normal response of 
the heart muscle to exercise or pregnancy [Mone et al., 1996], which 
results in an increase in the heart muscle mass and pumping ability. For 
instance, trained athletes have hearts with left ventricular mass 60% 
greater than untrained individuals. This type of hypertrophy leads to an 
increase in chamber radius and is called eccentric hypertrophy.  
Unhealthy or pathological hypertrophy is a response to stress, heart 
muscle injury, hypertension or hormones. In this case ventricular mass is 
increasing, but pumping capability remains insufficient to cover body 
needs. This type of hypertrophy shows an increase in wall thickness but 
not in the radius or capacity of the ventricle. It is termed concentric 
hypertrophy. As a response to pressure, cells add new sarcomeres in-
parallel to existing ones. 
Nowadays many factors and agents are known to induce hypertrophy:  
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Mechanical factors. Mechanical stretching is able to induce expression 
of specific genes, leading to the development of hypertrophy. 
Cytoskeletal myocardial LIM protein (MLP) is a mechanical sensor, 
triggering hypertrophic events in cardiomyocytes [Gehmlich et al., 
2008]. Stretching initiates protein kinase phosphorylation, which, in 
turns, activates transcription factors and thus regulates expression of 
corresponding genes in cardiac cells [Knöll et al., 2002].  
Peptides and catecholamines. Cardiotrophin and endothelin-1 (ET-1), 
angiotensin II (Ang II), insulin-like growth factor-II (IGF II), 
transforming growth factor-β (TGF-β), interleukin-1 and catecholamines 
are contributing to the myocardial hypertrophy development [Horio et 
al., 2010; Harada et al., 1999; Rosenkranz et al., 2002]. Mitogen-
activated protein kinase (MAPK) cascade, activated by Ang II or 
catecholamines, transfers in subsequent steps the signal right into the cell 
nucleus [Takano et al., 1996; Simm et al., 1998; Nigmatullina et al., 
2004].  
Calcium. Increased Ca
2+
 inside the cell can also trigger hypertrophy. 
Initial intracellular Ca
2+
-increase can be due to chronic pressure 
overload. Enhanced Ca
2+
 inside the cell activates a Ca
2+
-dependent 
phosphatase called calcineurin. Calcineurin in turns dephosphorylates 
the transcription factor NFAT3, which then enters the nucleus and 
activates genes involved in hypertrophic processes [Nigmatullina et al., 
2004]. 
On the cellular level, patients with hypertrophy and heart failure-
dependent loss of heart muscle function show changes in mechanisms of 
temporal [Ca
2+
]in
 
increase and
 
in expression of contractile proteins.  
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[Ca
2+
]in alterations suggest changes in the functioning of L-type Ca
2+
-
channels or in mechanisms of intracellular Ca
2+
-release from 
sarcoplasmic reticulum (SR) [Missiaen et al., 2000]. For instance, in 
hypertrophic animal models decreased ability of L-type Ca
2+
-channels to 
activate Ca
2+
-dependent-Ca
2+
 release was shown. 
Thus, being an important signalling molecule in the heart tissue, Ca
2+ 
not 
only contributes to the cellular contractility and activation of different 
signalling cascades and pathways, but also plays a role in the 
development of different heart diseases, among which are heart failure 
and hypertrophy. Therefore, normal and abnormal homeostasis of Ca
2+
, 
and its role in the physiological and pathophysiological conditions in the 
heart are crucial for investigation. Although, much has been done in this 
direction, still a lot of questions remain elusive.          
2.3. Ca
2+
 as a first messenger 
Ca
2+
 is a crucial molecule in our organism. Ca
2+
 ions are well known to 
be important second messengers. They trigger contractility, signal 
transduction, activation of enzymes. Intracellular calcium concentration 
is strictly regulated and can be changed on a short-term by opening of 
the calcium channels, its release from intracellular stores and work of 
Ca
2+
-pumps and adenosinetriphosphatases (ATPases). Extracellular 
Ca
2+
-concentration under physiological conditions is also quite stable. 
This can be achieved by strict regulation of Ca
2+
-homeostasis by 
different mechanisms. One of them is functioning of parathyroid glands. 
Via so-called calcium-sensing receptors (CaR), the parathyroidea detects 
Ca
2+
 levels outside the cell. If Ca
2+
-concentrations are low, it releases the 
parathyroid hormone (PTH) [Chattopadhyay et al., 2006]. PTH in turns 
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activates bones osteoclasts, leading to Ca
2+
-reabsorption. Vice versa, 
high extracellular Ca
2+
 levels, detected by CaR, inhibit PTH release.  
So thus, Ca
2+
 acts as an important first messenger via CaR, first shown in 
parathyroidea [Brown et al, 1993]. However, not only parathyroidea 
cells express these receptors. CaR were found in many organs involved 
in Ca
2+
 homeostasis, like kidneys, bones, intestines [Yamaguchi et al., 
1998; Chattopadhyay et al., 1998; Chattopadhyay et al., 2004; Riccardi 
et al., 1995] and also nervous and cardiovascular systems [Tfelt-Hansen 
et al., 2006; Yano et al., 2004]. 
2.4. CaR: structure and function 
The CaR belong to the family C of the G protein-coupled receptors 
(GPCRs). GPCRs are seven transmembrane receptors which are known 
as the largest group of cell surface membrane receptors and they have 
become the most important drug targets [Tfelt-Hansen et al., 2003]. 
CaR have three structural domains: large amino-terminal or extracellular 
domain (ECD, 612 amino acid residues), a seven transmembrane domain 
(TMD, 250 amino acid residues) and a C-terminal or intracellular 
domain (ICD, 216 amino acid residues). The receptor is modified by N-
glycosylation [Ray et al., 1998] and it is presented in homodimeric 
configuration on cell surface, which is crucial for its normal function 
[Bai et al., 1999]. The main extracellular Ca
2+
 binding site is ECD, but it 
was also shown that TMD takes part in Ca
2+
-sensing [Ray et al., 2002]. 
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Figure 1. CaR structure [modified from Smajilovic et al., 2008] 
The main ligand of the receptor is Ca
2+
. However, it has other ligands 
which belong to two different groups: direct agonists and allosteric 
modulators. Allosteric modulators change the affinity of the receptor to 
Ca
2+
 and other direct agonists. For example, CaR activation with Ca
2+
 is 
faster in the presence of calcimimetic AMG 073, which is a positive 
allosteric modulator of the receptor [Holstein et al., 2004]. Direct 
agonists have higher ability to bind to the receptor if they have high 
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positive charges. Moreover, CaR sense changes in ionic strength and pH 
[Quinn et al., 1998; Quinn et al., 2004] (Table 1).  
Direct agonists Positive Allosteric 
Modulators 
Negative Allosteric 
Modulators 
Cations (Ca
2+
, 
Mg
2+
, Gd
3+
, etc) 
L-type amino acids Calcilytics 
Polyamines 
(putrescine, 
spermine, 
spermidine) 
Calcimimetics N-tricyclo[3.3.1.13,7]dec-
1-yl-2-
quinoxalinecarboxamide 
(NPS2390) 
Antibiotics 
(neomycin, etc) 
  
pH   
Ionic strength   
 
Table 1. Agonists and antagonists of CaR 
 
CaR have a low-affinity, but their Hill coefficient is three-four 
(measured in bovine parathyroid cell) [Quinn et al, 1997]. Due to this 
property, the receptor is able to detect very small changes in extracellular 
Ca
2+
.  
Activation of the receptor leads to different intracellular events, 
depending on the cell type where it is expressed. In most of the cells 
CaR activation consistently leads to a phospholipase C (PLC)-dependent 
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formation of inositol triphosphate (IP3) which in turns releases Ca
2+
 ions 
form SR. This effect is mediated by an activation of receptor subunit 
Gαq [Tfelt-Hansen et al., 2006; Kifor et al., 1997]. These events also 
result in protein kinase C (PKC) mobilization, which in turns modulates 
activity of the CaR by negative feedback [Bai et al., 1998]. CaR activate 
via PLC phosphatidylinositol 4-kinase (PI4K) enzyme, which 
contributes to the first step in inositol lipid biosynthesis [Huang et al., 
2002].  
CaR also interact with Gαi which leads to the inhibition of adenylate 
cyclase (AC) and a drop in cellular cyclic adenosine monophosphate 
(cAMP) [Holstein et al., 2004].  
The CaR are supposed to be linked to several signalling pathways of 
different MAPKs. These pathways are responsible for proliferation, 
differentiation and regulation of peptide secretion and ion channel 
activity. [Kifor et al., 2001; Tfelt-hansen et al., 2005; Tfelt-Hansen et al., 
2004 ; Tfelt-Hansen et al., 2003].  
2.5. CaR in Ca
2+
-homeostasis and their expression in different 
organs 
CaR play an important role in Ca
2+
-homeostasis in the body. As 
mentioned previously, their expression was shown in parathyroid glands 
for the first time. Here they regulate the release of PTH. A decreased 
Ca
2+
 level in plasma results in CaR-mediated PTH release from 
parathyroid cells. PTH promotes Ca
2+
 reabsorption and bone resorption 
which leads to an increase in plasma Ca
2+
 levels [Chattopadhyay et al., 
2006]. 1.25(OH)2 vitamin D3 in kidney proximal tubular cells is being 
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synthesised under PTH and low Ca
2+
-level. Vitamin D3 metabolites 
trigger Ca
2+
 absorption in the intestine. CaR also modulate secretion of 
calcitonin from thyroid C cells, preventing inhibition of bone resorption 
by calcitonin under high plasma Ca
2+
. [Copp, 1994].   
Except for parathyroid glands, CaR expression has been demonstrated to 
be crucial for Ca
2+
-homeostasis in other organs, too, namely in kidneys, 
bones and the intestine [Riccardi et al., 1996; Yamaguchi et al., 1998; 
Chattopadhyay et al., 1998; Chattopadhyay et al., 2004]. 
CaR in kidney 
In the kidneys, the receptor is being expressed in almost all nephron 
segments including the ascending limb, distal and proximal tubules, 
collecting duct and glomeruli. The highest levels of CaR were found in 
the ascending limb [Graca et al., 2016]. Depending on the function of the 
specific tubular tracts, CaR inhibit the reabsorption of Ca
2+
, K
+
, Na
+
 and 
water. It also modulates signalling pathways of tubulocytes, which 
activate electrolyte or water reabsorption. In proximal tubules it is 
antagonising the effect of PTH by increasing phosphate reabsorption 
[Vezzoli et al., 2009]. 
CaR in gastrointestinal tract 
CaR are expressed in many segments of gastrointestinal tract, such as 
stomach, esophagus and colon [Magno et al., 2011; Chattopadhyay et al., 
1998]. In the esophagus, CaR stimulation increases phosphorylation of 
extracellular signal-regulated kinase secretion of interleukin-8 (IL-8) and 
intracellular Ca
2+
 mobilization [Justinich et al., 2008]. In the stomach 
CaR are expressed in different cell types and accordingly lead to 
17 
 
different responces and events. Pathways activated by CaR also differ in 
these cells. CaR in G-cells activate PLC pathways and modulate gastrin 
production [Buchan et al., 2001]. It was also shown that CaR activation 
in human mucous epithelial cells results in increased proliferation and 
intracellular Ca
2+
-levels [Rutten et al., 1999]. In parietal cells, the 
receptor regulates H
+
-K
+
-ATPase activity, which is necessary for gastric 
acid secretion [Dufner et al., 2005]. 
In the colon CaR agonists led to the activation of PLC induced pathways 
and also to cAMP inhibition [Cheng et al., 2002; Cheng et al., 2004]. It 
inhibits the forskolin-stimulated fluid secretion in colonic crypt cells 
[Cheng et al., 2004] and up-regulates expression and secretion of bone 
morphogenetic protein in myofibroblasts [Peiris et al., 2007]. Despite the 
CaR’s influence to proliferation, they negatively regulate cell 
proliferation and differentiation markers in cultured intestinal cell lines 
[Chakrabarty et al., 2003]. In conclusion, CaR regulate proliferation and 
differentiation processes in tissue specific manner.    
CaR in bones   
The first evidence of the presence of CaR in bone appeared in 1997 after 
experiments with osteoblastic MC3T3-E1 cell line [Yamaguchi et al., 
1998]. They have been shown to be expressed in osteoblastic [Chang et 
al., 1999] as well as in osteoclastic cells [Kameda et al., 1998]. In 
osteoblasts CaR induce cell proliferation [Dvorak et al., 2004], but 
mechanisms are still remain unclear. In osteoclasts, stimulation of the 
receptor results in the inhibition of a bone resorbing activity [Chang et 
al., 1999]. It also plays a role in differentiation and apoptosis of 
osteoclastic cells in PLC-dependent manner [Mentaverri et al., 2006]. 
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CaR in nervous system 
CaR are also presented in different parts of the central nervous system 
[Yano et al, 2004]. The highest level of CaR expression was detected in 
the subfornical organ, which is exposed to systemic fluid due to an 
absence of a blood brain barrier [Yano et al., 2004]. Stimulation of CaR 
in the neurons of the subfornical organ leads to a subthreshold, 
hyperpolarization activated inward current [Washburn et al., 2000]. 
There is also high expression of CaR in the hippocampus, where they 
regulate the opening of Ca
2+
-permeable, non-selective cation channels 
and Ca
2+
-activated K
+
-channels [Ye et al., 1997 A]. It has also been 
found that in hippocampus CaR can be activated by amyloid peptides. 
They are excessively produced in patients with Alzheimer’s disease [Ye 
et al., 1997 B]. Another protein, alipoprotein E, linked to Alzheimer’s 
disease, is also able to activate CaR [Conley et al., 2009]. Furthermore, 
CaR were shown to affect synaptic transmission [Phillips et al., 2008].  
CaR are not only expressed in neurons. Their presence was shown in 
microglia [Chattopadhyay et al., 1999], oligodendrocytes 
[Chattopadhyay et al., 1998] and astrocytes [Chattopadhyay et al., 2000]. 
There they regulate Ca
2+
-activated K
+
-chanels and promote parathyroid 
hormone-related protein (PTHrP) secretion respectively [Chattopadhyay 
et al., 1999; Chattopadhyay et al., 1998].  
Other groups showed that the receptor is also expressed in mammary 
glands [Cheng et al., 1998], epidermis [Bikle et al., 1996] and some 
other organs. 
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In summary, CaR were detected in many different tissues where its role 
also varies. They are responsible for an activation of many different 
pathways leading to many biological actions in the body. Thus they are 
interesting therapeutic targets. Nevertheless, more investigation on their 
role and expression should be done.  
 
2.6. CaR in cardiovascular system 
The crucial role of Ca
2+
-ions in the regulation of different physiological 
functions in the heart is known since long ago. Now it is well accepted 
that Ca
2+
-ions are very important second messengers in the heart tissue. 
Increased Ca
2+
-concentration inside the cardiomyocyte, via Ca
2+
-
dependent Ca
2+
-release form SR, is required for the electromechanical 
coupling of heart cells. With every heart beat intracellular Ca
2+
-
concentration is elevated approximately 10-fold from basic level. 
Therefore, intracellular Ca
2+
-concentration is important to be regulated. 
Several mechanisms exist to meet this demand such as a regulation of 
the activity of Ca
2+
-channels, pumps, proteins and exchangers.  
As explained above, Ca
2+
 is also able to act as a first messenger in 
cardiac tissue via CaR on the cardiomyocytes plasma membrane.  
First results indicating CaR expression in the heart appeared in 2003 
when Wang et al. identified CaR in rat heart tissue by real-time 
polymerase chain reaction (RT-PCR) and immunoblot analysis [Wang et 
al., 2003]. In the cardiovascular system CaR are expressed in  neonatal 
and adult heart muscle cells [Tfelt-Hansen et al., 2006; Wang et al., 
2003] as well as in vascular smooth muscle cells [Smajilovic et al., 
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2006] and endothelial cells [Weston et al., 2005]. A group of scientists 
has also reported a presence of CaR in perivascular nerves of isolated rat 
arteries and showed that increased [Ca
2+
]out causes nerve-dependent 
relaxation of pre-contracted arteries [Bukoski et al., 1997]. In vascular 
smooth muscle cells CaR are involved in modulation of vessel tone and 
thus blood pressure regulation [Smajilovic et al., 2008]. CaR in 
endothelial cells adjust opening of Ca
2+
-sensitive K
+
-channels [Weston 
et al., 2005] and thus, also contributing to the blood pressure control. 
mRNA and protein of the CaR were detected in both atrial and 
ventricular cardiomyocytes of Sprague–Dawley rats [Wang et al., 2003]. 
It is Gαq coupled. Intracellular Ca2+ and IP3 levels were elevated after 
activation of cardiovascular CaR [Tfelt-Hansen et al., 2006]. This 
finding indicates PLC-linked CaR activation in the heart. CaR agonists 
also led to MAPK signalling pathways activation [Holstein et al., 2004]. 
2.7. CaR and receptor activity-modifying proteins interaction 
CaR were reported to require activity of the receptor activity modifying 
proteins (RAMPs) to be presented on cell surface [Bouschet et al., 2005]. 
RAMPs are single transmembrane proteins which are expressed in many 
cells [McLatchie et al., 1998; Morfis et al., 2003]. Three types of these 
receptors were shown: RAMP1, RAMP2 and RAMP3 respectively 
[McLatchie et al., 1998]. Bouschet at al demonstrated that RAMP1 and 
RAMP 3 are important to stimulate CaR traffic to plasma membrane in 
HEK293 cells [Bouschet et al., 2005]. CaR were the first members from 
its class (C class, GPCRs family) shown to require RAMPs activity. 
RAMP1 and RAMP3 levels determine the presence or absence of 
functional CaR. Interestingly the expression of both RAMPs was 
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increased in cardiac tissue and myocytes in rats with chronic heart 
failure [Cueille et al., 2002].   
2.8. CaR in heart disease 
Ca
2+
 control is very important for the physiological function of the heart. 
Therefore, plasma Ca
2+
 levels as well as intracellular Ca
2+
 are strictly 
controlled by various mechanism mentioned above (Ca
2+
-uptake, Ca
2+
-
release and plasma Ca
2+
-homeostasis). During the development of heart 
failure, these mechanisms are being violated. Dysfunction of the 
intracellular Ca
2+
-cycle is crucial for the pathogenesis of heart failure 
[Orrenius et al., 2003]. The sarcoplasmatic reticulum (SR), as an 
intracellular Ca
2+
-storage organelle, is sensitive to intracellular Ca
2+
-
alterations and disturbances. The exhaustion of Ca
2+
 from the SR can 
disrupt its function and lead to SR stress, which in turns, leads to cell 
damage and dysfunction. Ultimately, this can result in apoptosis 
[Kaufman, 2002]. SR stress is also involved in several heart diseases, 
namely hypertension, myocardial ischemia and dilated cardiomyopathy 
[Ni et al., 2011]. Main mechanism leading to an increased intracellular 
Ca
2+
 is Ca
2+
-dependent-Ca
2+
-release via ryanodine receptors (RyRs). 
Nevertheless, IP3-receptors (IP3R) on SR membrane play a role in Ca
2+
-
release [Mackenzie et al., 2002]. Some studies have demonstrated that 
IP3R expression was enhanced in patients with end-stage chronic heart 
failure, and RyRs, in contrast, were downregulated [Go et al., 1995]. 
These findings lead to the possible role of CaR in the development of 
different heart pathologies, as CaR are known to trigger IP3-dependent 
Ca
2+
-release.  
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It was also shown that IP3R play a role in SR-mitochondria cross-talk, 
leading to an increased Ca
2+
-uptake by mitochondria [Seguchi et al., 
2005]. This SR-mitochondria interaction is observed in failing hearts 
and inducing programmed cardiomyocytes death [Pacher et al., 2001]. 
Lu et al suggested that CaR signalling play key role in cardiomyocyte 
apoptosis via interplay between SR and mitochondria in the progression 
of heart failure. This effect of the receptor is IP3R mediated [Lu et al., 
2013]. 
Development of apoptosis was also reported in neonatal rat ventricular 
cardiomyocytes under CaR stimulation. This effect is promoted by 
MAPK and caspase 9 signalling pathways activation [Sun et al., 2006]. 
Participation of CaR in neonatal rat cardiomyocytes apoptosis induced 
by ischemia-reperfusion (I/R) injury was also shown [Jiang et al., 2008]. 
I/R injury induced CaR enhanced expression and increased rate of 
apoptosis.  
Interestingly, inhibition of CaR during post-conditioning of the heart 
significantly improved function and decreased apoptosis rate after I/R 
injury [Gan et al., 2012].  
Other events that may involve CaR activation are hypertension and 
hypertrophy development. Group of scientists demonstrated involvement 
of the receptor in Ang II-induced hypertrophy [Wang et al., 2008]. But 
so far not many data indicated the functional role of the receptor during 
cardiac hypertrophy development. 
2.9. ET-1 and cardiac hypertrophy development 
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ET-1 is a potent vasoconstrictor peptide consisting of 21 amino acids. In 
cardiovascular system it is produced by vascular endothelial cells, 
endocardial endothelial cells and cardiomyocytes [Yanagisawa et al., 
1988; Rubanyi and Polokoff, 1994; Mebazaa et al., 1993; Cingolani et 
al., 2006] with the help of endothelin-converting enzyme 1 (ECE1) as a 
respond to hypertension, stress, diabetes, etc. Its action is provided via 
G-protein-coupled receptors. There are two main isoforms of ET-
receptors: ET receptors type A (ETA) and ET receptors type B (ETB) 
[Fareh et al., 1996]. ET-1 induces positive inotropic effect in acute way, 
negative inotropic and growth stimulation effects in long-term exposure 
[Hinrichs et al., 2011]. 
High plasma levels of ET-1 and increased expression of ET-receptors 
have been found in many models of heart failure [Omland et al., 1994].  
Interestingly, two subtypes of ETB receptors were recently investigated, 
that are PD142893 sensitive (ETB1) or resistant (ETB2). It is supposed 
that ETB receptors participate in the development of cardiac hypertrophy 
[Lee et al., 2004]. 
Group of scientistsShiraishi et al. showed the relation between CaR and 
increased ET-1 expression in kidney [Shiraishi et al., 2003]. This leads 
to the centre questions addressed in this study. 
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3. Aims 
The aims of the study was to identify the role of CaR in cardiac 
physiology and the pathophysiology of heart hypertrophy. Three aims 
were addressed: 
 to investigate CaR expression in isolated rat cardiomyocytes 
and cardiac tissue under physiological and pathophysiological 
conditions. 
 to determine the functional role of the CaR in basal 
electromechanical coupling of the cardiac muscle cells. 
 to study whether CaR coupling is modified in the development 
cardiac hypertrophy 
 to clarify mechanisms, involving CaR in these events. 
 to identify the relationship between ET-1, RAMP-1, and CaR 
during cardiac hypertrophy. 
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4. Material and Methods 
4.1. Buffers and solutions 
4.1.1. Powell Medium (All Chemicals provided by Carl Roth, 
Germany): 
NaCl  110.0 mМ 6.43 g/l 
KCl 2.6 mМ 0.19 g/l 
KH2PO4 1.2 mМ 0.16 g/l 
MgSO4 1.2 mМ 0.30 g/l 
HEPES 25.0 mМ 5,96 g/l 
Glucose 11.0 mМ 2.18 g/l 
 
4.1.2. Collagenase solution: 
- 5 ml of warmed up and oxygenated Powell Medium 
- 12.5 µl of 0.1 M CaCl2 solution  
- 25 mg collagenase (type 2, CLS II, Biochrom), the 
amount is batch addicted 
4.1.3. CCT Medium (10L): 
  2 packs M199 (Biochrom, Germany) dissolved in 10L 
dist. H2O 
26 
 
 36 g/l HEPES (Carl Roth, Germany) 
 6.56 g  5мМ Creatine (Sigma Aldrich, Germany) 
 3.95 g 5 мМ Carnitin (Sigma Aldrich, Germany) 
 6.26 g 5 мМ Taurine (Sigma Aldrich, Germany) 
 10 mg Arabinofuranosyl-cytosine (Sigma Aldrich, 
Germany) 
pH= 7.4 
 
 
4.1.4. Cell lysis buffer (2 ml): 
- 1770 µl lysis buffer (self-made: 50mM Tris with HCl 
ph 6,7 + 2% SDS) 
- 20 µl protease inhibitor (Sigma Aldrich, Germany) 
- 10 µl phosphotase inhibitor (Sigma Aldrich, Germany) 
- 200 µl Dithiothreitol (DDT) (Roche Life Sciences, 
USA) 
+ Benzonase (1:30) 5 µl per plate after 1
st
 rotation step (Merck, 
Germany) 
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4.1.5. Tissue lysis buffer (1 ml): 
- 100 µl lysis buffer (Cell Signaling Technology, 
Germany) 
- 900 µl H2O 
- 10 µl Phenylmethane sulfonyl fluorid, PMSF (0.1 M) 
(Life Technologies,   USA) 
4.1.6. Contraction buffer (to measure Ca
2+
-transients and load-free cell 
shortening under different Ca
2+
-concentrations): 
NaCl 125 mM 
KH2PO4 1.2 mM 
KCl 2.6 mM 
MgSO4 1.2 mM 
Glucose 10 mM 
HEPES 10 mM 
pH = 7.4 
4.1.7. FURA-2 AM loading buffer: 
- 5µl FURA-2 AM (50mg FURA-2AM (Life 
Technologies, USA) in 300µl DMSO) 
- 1 ml contraction buffer 
 4.1.8. MOPS Running buffer (1x): 
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- 50 ml MOPS SDS Running Buffer (20x) (NuPAGE, 
Life Technologies, USA) 
- 950 H2O 
4.1.9. Transfer Buffer (500 ml): 
- 374.5 ml H2O 
- 25 ml transfer buffer (Life Technologies, USA) 
- 100 ml methanol (Carl Roth, Germany) 
- 500 µl antioxidant (contains N,N-
Dimethylformarmide) (Life Technologies, USA) 
 
4.1.10. Blocking buffer (for one membrane): 
- 10 ml 1% TBS (AppliChem, GmbH, Germany) 
- 0.5 g BSA (Albumin Fraction V, Roth, Germany) 
4.1.11 Primary antibody solution (for one membrane): 
- 10 ml 1% TBS (AppliChem, GmbH, Germany) 
- 0.5 g BSA (Albumin Fraction V, Roth, Germany) 
- Primary antibody according to company protocol 
(Table 1) 
- 10 µl Tween (AppliChem, GmbH, Germany) 
4.1.12. Secondary antibody solution (for one membrane): 
- 10 ml 1% TBS (AppliChem, GmbH, Germany) 
- 0.5 g BSA (Albumin Fraction V, Roth, Germany) 
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- Secondary antibody according to company protocol 
(Table 2) 
- 10 µl Tween (AppliChem, GmbH, Germany) 
4.1.13 PKC Kinase Activity Assay Kit (Assay Designs, Ann Arbor, 
USA), amount per well: 
- PKC Substrate Microtiter Plate, precoated with 
substrate peptide for PKC (1 plate – 96 wells) 
- 40 µl Phosphospecific Substrate Antibody (1 µg/ml  
solution of rabbit polyclonal antibody specific for 
phosphorylated PKC substrat) 
- 40 µl Anti-Rabbit IgG: HRP Conjugate (1 µg/ml 
solution solution of horseradish peroxidase conjugated goat 
antirabbit IgG) diluted in Antibody Dilution Buffer (1mg/ml) 
- 50 µl Kinase assay dilution buffer (for ATP and 
samples dilution) 
- 10 µl ATP 
- 40 µl Active PKC (20 µg/ml) 
- 100 µl 20x Wash buffer  
- 60 µl TMB Substrate (Stabilized tetramethylbenzidine 
substrate)  
- 20 µl Stop Solution  (Acid solution to stop color 
reaction) 
 
4.1.14 DNA mix (for 1 sample): 
- 2 µl 5*RT-Buffer 
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- 1 µl Oligo d tang 
- 1 µl dNTP’s 
- 0.5 µl DTT (0.1 M) (Invitrogen, Canada) 
- 0.2 µl RNAsin (40 U/µl) (Promega, USA) 
- 0.3 µl M-MLV reverse transcriptase (200 U/µl) 
(Invitrogen, USA) 
 
4.1.15. Primer mix (for 1 sample): 
- 10 µl IQ Cyber Green Supermix (BIO-RAD, Germany) 
- 0.6 µl Primer (Table 2) 
- 6.4 µl H2O 
4.1.16. Agarose-gel loading buffer: 
- 1 ml 10xTAE buffer (BioLine, Germany) 
- 0.5 ml Glycerin (Karl Roth, Germany) 
- Bromphenolblue (add a little bit untill solution is blue) 
(Merck, Germany)  
4.1.17. Loading marker (for 1 well): 
- 5 µl 100 bp DNA ladder (Fermentas, GmbH, Life 
Sciences, Germany) 
- 10 µl Loading buffer 
- 58 µl 1XTAE-buffer  
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4.2 Methods 
4.2.1. Isolation of cardiomyocytes 
Cells were isolated from male Wistar rats aged three to four moths 
according to the guideline of animal welfare. Rats were killed under 
deep 4-5% Isofluran (Baxter GmbH, Germany) anesthesia, hearts with 
intact aorta were excised from the opened chest and placed into ice-cold 
salt solution (0.9% NaCl). Lung, esophagus, trachea and thymus were 
removed. Aorta was shortened at the second vessel. 
Subsequently, the heart was rinsed to the Langendorff perfusion system 
which was filled with 80 ml The Powell Medium had been warmed up 
and oxygenated with carbogen (95%O2, 5%CO2). The heart was rinsed, 
putting cannula of the perfusion system inside aorta lumen and fixing it 
in this position with a clip and a rope after.    
The hearts were washed from blood with Powell Medium until 45 ml 
remained in Langendorff system. Afterwards, the system was closed and 
5 ml of prepared collagenase solution were added.  
Perfusion time was 25 min. After the hearts (without atria) had been 
removed from system, the ventricles were separated from the atria and 
cut into small pieces using a chopper (0.7 mm). The ventricles were 
transferred on a watch glass and chopping continued with two scalpels.  
The resulting homogenate was exposed to collagenase solution for five 
more minutes and then filtered using nylon mesh. 
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Subsequently, three centrifugation steps were performed (Allegra 21 
centrifuge, Beckman Coulter, Germany): 
- 400 rpm 3 min (250 µM CaCl2)  
- 400 rpm 2 min (500 µM CaCl2) 
- 300 rpm 1 min (1 mM CaCl2) 
Afterwards, the cells were plated (with CCT medium or contraction 
buffer with 0.5 mM, 1 mM, 1.2 mM, 2 mM or 4 mM CaCl2) on FCS-
precoated culture dishes (precoated with 4% (v/v) FCS (Fetal Cow 
Serum, PAA Laboratories GmbH, Austria) and 2% (v/v) penicillin and 
streptomycin (Gibco, Life Technologies, Germany)). They were 
incubated for one hour (incubator BBD 6220 Heraeus, Thermo 
Scientific, Germany) and then exposed to different analysis.  
 
4.2.2. Determination of load-free cell shortening  
Cell contraction was measured at room temperature and analyzed using 
cell-edge-detection system as described before [Langer et al., 2003]. The 
cells were stimulated via two AgCl electrodes with biphasic electrical 
stimuli, composed of two equal but opposite rectangular 50-V stimuli of 
5 ms duration. Cardiomyocytes were exposed to 2 Hz stimulation. 
Contraction signals were recorded every 15 s. The mean of these four 
measurements were used to define the shortening of each cell. A special 
black and white linear camera was used to measure the cells’ lengths 
(data recording at 500 Hz). The cells were situated in CCT Medium with 
1.25 mM extracellular Ca
2+
-concentration. In some series of experiments 
the effects of different extracellular Ca
2+
-concentrations were analyzed. 
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In this part of experiments, cells were incubated in a cell culture buffer 
as described previously [Piper et al., 1989]. Cells were then situated in 
contraction buffer with 0.5, 1.0, 1.25, 2.0 or 4.0 mM Ca
2+
-concentrations 
respectively. Data is presented as cell shortening normalized to cell 
diastolic length (dL/L(%)). 
 
 
Figure 2. a. Cell-edge-detection system (SH Heidelberg, Germany). b. 
screening of cardiomyocyte via black and white linear camera. c. Linear 
camera. Cell edges detected by linear camera calculated by software Cell 
(Heidelberg, Germany) and expressed as difference between systolic and 
diastolic cell lengths in percent (dL/L,%)  
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4.2.3. Quantification of Ca
2+
-transients 
 
To investigate further the effects of CaR activation on cell shortening, 
systolic Ca
2+
-transients were measured. Fluorescent dye FURA-2 
acetoxymethyl ester (FURA AM – see Buffers and Solutions) was used 
[Ladilov et al., 2003]. Cells were isolated as described previously (see 
cardiomyocytes isolation). Isolated cardiomyocytes were placed onto 
laminin-precoated glass cover-slips (Roth, Germany) in M199. 
Immediately before systolic Ca
2+
 measurements, M199 was replaced by 
FURA-2 AM loading buffer (see buffers and solutions) for 30 min at 37 
o
C. After loading, the cells were washed with contraction buffer (see 
buffers and solutions) to allow hydrolysis of acetoxymethyl esters within 
the cells. When added to the cell, FURA-2AM crosses cell membrane 
and once inside the cell, acetoxymethyl is removed by cellular esterases. 
Cover slips with loaded cells were introduced into a gas-tight, 
temperature-controlled (37
o
C), transparent perfusion chamber positioned 
in the light path of an invert microscope (Nikon eclipse TS100). 
Alternation excitation of the fluorescence dye at wavelength of 340/380 
nm was performed with an AR-caution system (ION optix Corp.) 
adapted to microscope. ION Optix Corp. system was used to capture 
light emitted (500-520 nm) from the single fluorescent cell and 
background area. The data was analyzed as the ratio of light emitted at 
340-to-380 nm wavelength. Background area and non-stimulated 
sarcomeres of the cardiomyocyte were measured first (fluorescence of 
cells were 10-20 times higher that background fluorescence), followed 
by measurements of 1 Hz Myo Pacer (ION Optic Corp., Germany) 
stimulated cell sarcomeres.      
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4.2.4. Tensometry  
Functional properties of rat myocardium were examined on heart muscle 
strips in vitro. BiopacSystems setup (USA) with isometric transducer 
TSD 125C was used (Fig. 3). 
Rats were narcotized with Isofluran (4-5%). The heart was excised from 
the chest and then placed into Powell Medium with 1,5 mM CaCl2. 
Ventricles and atria were cut in small strips (4-6 mm length, 0.8-1 mm 
diameter) and put into the 20 ml bath with oxygenated (95% O2, 5% 
CO2) Powell Medium at room temperature. Upper edge of the strips 
preparations were connected to tense transducer via a metal lath (plank). 
Lower edge was fixed to the bath base.  
The strips were stimulated with 2 silver plated electrodes (stimulant 
ESL-2, Russia) with 0.1 Hz frequency, 40 mV amplitude, and 5 ms 
duration.  
Strips were placed to bath Powell Medium and elaboration during 40-60 
min was performed. When signals were stable, control parameters were 
registered with original software (Elf, A.V. Zaharov, Russia). Tested 
substances were added directly to the baths with muscle strips 
preparations. Drug effects were calculated in percent comparison to the 
control values. Signals were calculated using Elf, Origin and Excel. 
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Figure 3. Tensometric setup scheme 
 
4.2.5. Rat model of nitric oxide deficiency 
The experimental model of nitric oxide-deficiency (NO-deficiency) was 
used to investigate left ventricular CaR and ET-receptors expression. 
Three months old Wistar rats were divided into four groups and kept in 
individual cages. Animals had unlimited access to water and food. Non-
specific NO-synthase (NOS) inhibitor L-NAME (L-nitro-argenine 
methyl ester hydrochlorid, Sigma Aldrich, Switzerland) was added to 
drinking water (7.5mg/day) during 1 month in the first animal group and 
during 6 months in the second animal group. Group 3 and 4 consisted of 
animals, not treated with L-NAME in corresponding age with 1 and 2 
group [Schreckenberg et al., 2015]. Heart tissue samples were collected 
thereafter for qRT-PCR and Western Blot analysis. 
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These experiments have been described before in greater details 
[Schreckenberg et al., 2015]. Tissue samples from these experiments 
have been used for this study. 
4.2.6. Tissue lysis 
To prepare tissue samples for immunoblot analysis isolated hearts were 
cut in small pieces (0.1 g), collected to the tubes and supplied with 500 
µl tissue lysis buffer (10 times dilution) provided by Cell Signaling 
Technology (Germany). Samples were then homogenized (6,000 upm - 
Homogenisator Precellys24, Peqlab Biotechnology, GmbH Germany) in 
Precell-Tubes 2 times for 20 sec. After 10 min cold homogenates 
exposed to 30 s sonication (60% amplitude, 0.7 cycle) using Ultra Sonic 
Processor (UP100H, Hielscher, Germany) and 10 min spin in centrifuge 
(14,000g, 4
o
C, Allegra 25R centrifuge, Beckman Coulter). Supernatants 
were collected and diluted in the ratio 1:50 with water. In the end 40 µl 
of Laemmli buffer (Sigma, USA) were added to each 100 µl of samples.  
4.2.7. Cell lysis 
Cardiomyocytes were isolated as described before and collected for 
protein analysis. Cell culture medium was removed from plates and cells 
were washed with ice-cold PBS. Each culture dish was supplied with 
100 µl of lysis buffer (see Buffers and Solutions) and placed onto the 
Vortex (Unimax 1010, Heidolph Instruments) for 30 min. After 15 min 
Benzonase were added to each culture dish and rotation continued. In the 
end cell suspension was scraped with cell scrapers (Sarstedt Inc, USA) 
and collected to 1.5 ml tubes (Sarstedt Inc, USA). Samples were frozen 
at -20
o
C or Western Blot analysis was directly performed. 
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4.2.8. Western Blot analysis 
To perform Immunoblot analysis tissue or cell lysates were diluted with 
20 µl of Bromphenol Blue (BPB, Merck, Germany) and warmed up in 
Thermostat (5 min, 95
o
C; Techne DRI-BLOCK DB-20, Labtech 
International). The protein samples were separated using gel 
electrophoresis. Samples with BPB (20 µl each) were loaded onto the 
wells of the 15% SDS-PAGE gel (Invitrogen, USA) which was placed 
into the chamber with MOPS running buffer (Buffers and Solutions). 
First well of each gel was loaded with Marker (Spectra Multicolor, 
Thermo Scientific, USA). 200 V was applied along the gel for one hour. 
Proteins were spread according to their molecular weight. 
To be able to detect and quantify proteins, loaded gels were next 
exposed to the second electroblotting step of 30 V together with 
Nitrocellulose Transfer Membranes (Whatman GmbH, Germany) in the 
chamber containing transfer buffer (Buffers and Solutions). After 60-75 
min proteins together with marker were transferred onto membrane. To 
avoid subsequent non-specific bindings of antibodies, transfer 
membranes were incubated with blocking buffer (Buffers and Solutions) 
for 1 hour under gentle agitation.  
To detect targeted proteins, special antibodies against them were used 
(Table 2). After blocking membranes with transferred proteins were 
exposed to the dilute solution of primary antibodies (Buffers and 
Solutions) over night at 4°C under agitation. To wash unbound probes of 
primary antibodies away 1% TBS together with 0.1% Tween were used. 
Secondary antibodies solution directed at a species-specific portion 
(Table 2) of the primary antibody were used thereafter. Secondary 
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antibodies are able to bind chemiluminescent agents, and thus visualize 
certain protein level. Several secondary antibodies bind to one primary 
antibody which enhances the signal.  
To visualize the targeted protein level Chemiluminescent Substrate 
(Thermo Scientific, USA) and chamber (Peqlab, Biotechnologie, 
Germany) were used. Quantity One software detected and calculated 
protein levels (BioRad, Germany). 
Name Catalog number Source 
Anti-CaR SAB4503369, Sigma 
Aldrich, Germany 
Antibody produced 
in rabbit 
Anti- RAMP1 Sc-11379, Santa Cruz 
Biotechnology, Inc, 
Germany 
Rabbit polyclonal 
antibody 
Anti-GAPDH CB1001, Merck, 
Germany 
Mouse monoclonal 
antibody 
Anti-β-actin A2668, Sigma 
Aldrich, Germany 
Antibody produced 
in rabbit 
Anti-Phospholamban 
(FL-52) 
Sc-30142, Santa Cruz 
Biotechnology, Inc, 
Germany  
Rabbit polyclonal 
antibody 
Anti-P-
Phospholamban, 
phosphorylated form of 
phospholamban (Ser 
16)  
Sc-12963 Santa Cruz 
Biotechnology, Inc, 
Germany 
Goat polyclonal 
antibody 
Table 2. Antibodies used in the study 
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4.2.9. Determination of PKC activity 
In order to quantify PKC activity the nonradioactive activity assay 
(Assay Designs Ins, Ann Arbor, USA) was used. The concept is based 
on a solid phase enzyme-linked immune-absorbent assay that utilizes a 
specific substrate for PKC and a specific antibody against the 
phosphorylated form of the substrate. Isolated cadriomyocytes, exposed 
to the cell shortening measurements and CaR agonists stimulation, were 
thereafter collected and lysed as described before. The clear supernatant 
was used to measure the entire protein concentration and the PKC 
activity according to the manufacturer suggestions (PKC Activity Assay 
Kit, Assay Designs, Ann Arbor, USA).  
PKC Substrate Microtiter Plate wells were soaked with Kinase Assay 
Dilution Buffer for 10 min at room temperature right before sample 
addition. 40 µl of samples and control (blank) were added to appropriate 
wells thereafter at 30
o
C. Subsequent procedure was made in room 
temperature. Reaction in each well was initiated by ATP supplement. 
After 90 min reaction was stopped by emptying the wells and 
phosphospecific substrate antibody was added for more 60 min.  Wash 
buffer was used four times to wash wells after antibody incubation. 
Next, samples were incubated with HRP Conjugate (30 min, room 
temperature) and again washed four times with washing buffer. TMB 
substrate was added to the samples for substrate stabilization with 
subsequent Stop solution incubation. Sample analysis was performed 
using ELISA reader (TECAN, Germany) at 450 nm. Results were 
transferred and calculated in Excel. Relative kinase activity was taken 
as: 
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Average Absorbance (sample) – Average Absorbance (blank) 
Quantity of crude protein used per assay 
 
 
4.2.10. Collection of cells for the PCR analysis 
Cell isolation procedure was performed as described before. Isolated 
cells were plated onto 2 ml Petri dishes precoated with FCS. Cultures 
were stimulated according to requested conditions during 4 h. After 
incubation, cells were washed twice with ice-cold PBS, scrapped from 
plates and collected for the qRT-PCR analysis.  
4.2.11. RNA isolation and quantification 
Total cellular RNA was extracted using Trizol reagent (Invitrogen, 
USA). Heart tissue was cut in small pieces and put to Precell-Tubes. 1 
ml Trizol was added to each tube and homogenization step was 
performed twice (5000 rpm, 20 s).  
In case of isolated cells, 1 ml of Trizol was added to each sample and 
gently mixed for 5 min at room temperature.  
For RNA purification 200 µl of chloroform was added to each sample, 
carefully shacked and spinned in centrifuge (12000 g, 4
o
C; Allegra 25R, 
Beckman Coulter, Germany) for 15 min. Colorless aqueous phase was 
collected from each tube after centrifugation. 500 µl isopropanol was 
added to each tube and stored at room temperature for 20 min and then 
centrifugation step was repeated. Supernatant was gently removed and 
RNA precipitate was washed with 75% ethanol under centrifugation. 
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RNA samples then were air-dried for 1 h and dissolved with water (50 
µl). RNA concentration was quantified with NanoDrop ND-2000 
(peqLab Biotechnologie GmbH). Quantity of total RNA and hydrolyzed 
RNA was determined with the ND-2000 software. According to RNA 
quantity, water was added to each sample to a final 15 µl volume for the 
3-fold dilution. cDNA then was synthetized using DNA-mix (see buffers 
and solutions) and cDNA thermal cycler (Cyclogene, Techne, Germany). 
Obtained cDNA samples were diluted with water in ratio 1:10 and then 
qRT-PCR was performed.  
4.2.12. qRT- PCR 
3 µl of dissolved (1:10) cDNA samples were supplied with 17µl primer 
mix (see Buffers and Solutions) and exposed to qRT-PCR analysis using 
amplificator. cDNA fragments were amplified by 45 cycles of PCR 
(denaturing, annealing and extension) according to primer protocol. The 
gene products were quantified using SYBR Green assays (BioRad, 
Germany). Melting curve analysis was performed to quantify certain 
PCR product. To find difference in expression, samples were normalized 
to the expression of the reference gene and related to the control 
treatment. GAPDH and B2M were used as reference genes (Table 3). 
The data was analyzed by relative quantitation 2 
- △△ CT method. 
Gene Forward 
 
Reverse 
CaR  AAGTGCCCGGATGACTTC
TG 
GGTTGGTGGCCTTGACGAT
A 
ETA ATTTGGCCCTGCCTAGCA CCCACCATTCCCACGATGA
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receptor AT A 
ETB 
receptor 
GCTAGCCATCACTGCGAT
CT 
TGTCTTGGCCACTTCTCGT
C 
ECE-1 TCTGGCCAACATCACCAT
CC 
TAGACCACGATGGGCTCA
GA 
RAMP-1 AGCATCCTCTGCCCTTTC
ATT 
GACCACCAGGGCAGTCAT
G 
B2M GCCGTCGTGCTTGCCATT
C 
CTGAGGTGGGTGGAACTG
AGAC 
HPRT CCAGCGTCGTGATTAGTG
AT 
CAAGTCTTTCAGTCCTGTC
C 
 
Table 3. Primer sequences used in the study 
4.2.13. Agarose gel electrophoresis of cDNA fragments 
To visualise cDNA amplificated fragments Agarose gel electrophoresis 
was performed after RT-PCR. Agarose gel was created by mixing 1 g of 
Agarose with 1xTAE-Buffer (see Buffers and Solutions) and boiling 
them together in microwave up to 60
o
C.  Mixture was supplied by 3.75 
µl SYBR Safe dye (BioRad, Germany) and placed to a gel 
electrophoresis camera for 30 min until it was solid. Cuts for gel wells 
were made.  
10 µl of samples were mixed with 2 µl of Loading Buffer (see Buffers 
and Solutions) and loaded into the wells. First well was filled by 
Loading Marker (see Buffers and Solutions). 75 V-voltage was applied 
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for the samples during 30 min. cDNA fragment bands were detected 
under UV- light of 366 nm (UV-chamber, PeqLab, Biotechnologie, 
GmbH, Germany) and captured by camera (Olympus SP-500UZ)  
4.3. Statistics 
 
Data are expressed as raw data points or means  SD/SEM as indicated 
in the legend to the figures. ANOVA and the Student-Newman-Keuls 
test for post hoc analysis were used to analyze experiments in which 
more than one group was compared. In cases in which only two groups 
were compared, Student’s t-test or Mann-Whitney test was employed, 
depending on a normal distribution of samples (Levene test). P levels are 
indicated as expressed in the legend to the figures. 
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5. Results 
5.1. The role of the CaR in physiological heart functioning  
5.1.1. Expression of CaR in adult rat cardiomyocytes 
Expression of CaR in neonatal rat cardiomyocytes and cardiac tissue was 
reported previously in Sprague–Dawley rats [Tfelt-Hansen et al., 2006]. 
So here we start with confirming these findings for cardiomyocytes 
derived from adult Wistar rats. In different preparations we were able to 
detect stable mRNA level of CaR (Fig.4a). Moreover, CaR protein level 
is consistently presented in isolated heart cells (Fig.4b). By 
downregulation of CaR with small inhibitory RNA (siRNA) specificity 
of the protein band was confirmed. 
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Figure 4. CaR expression in ventricular cardiomyocytes. a. mRNA level 
of CaR in 3 different samples of isolated cardiomyocytes detected by 
RT-PCR, n=3 b. CaR protein level detected by Western Blot in 
cardiomyocytes cultured for 24 h in presence of siRNA vs CaR (0.05 
µM), scramble RNA (0.05 µM) or control, n=3. 
It is worth noting, that CaR expression was shown in left and right 
ventricular and also atrial tissues (Fig. 5). There seems to be a tendency 
to lower expression in right ventricles and atria.   
 
Figure 5. CaR protein expression in left ventricular (LV), right 
ventricular (RV) and atrial (Atr) tissue. 
 
5.1.2. Ca
2+
-concentration-dependent CaR activity  
Ca
2+
 ions are main natural agonists of the CaR. However, Ca
2+
 can also 
affect cell shortening in CaR-independent way. To distinguish between 
the action of CaR and the effect of Ca
2+
 up-take on cell shortening, 
extracellular Ca
2+
-concentration on NPS-sensitive cell shortening was 
determined. At near physiological extracellular Ca
2+
-concentrations (1-
1.25 mM) non-specific inhibitor of CaR NPS2390 significantly 
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decreased load-free cell shortening (Fig. 6). At higher Ca
2+
-
concentrations the effect of NPS2390 was diminished. 
 
 
Figure 6. Effect of extracellular Ca
2+
-concentration on NPS-sensitive 
cell shortening. Extracellular Ca
2+
-concentration was set to 0.5-4 mM. 
NPS – NPS2390 (10 µM). Load-free cell shortening is expressed as 
shortening amplitude normalized to diastolic cell lengths (dL/L%). Data 
are means ± SEM from n=27, *p<0.05 vs untreated controls. Blue graph 
is indicating control values, red – cell shortening under NPS2390.    
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5.1.3. Effect of CaR acute inhibition on cardiac performance 
To find out whether CaR contribute to the basal heart function, we 
blocked receptors by administration of NPS2390. NPS2390 significantly 
reduced contraction force of tissue stripes derived from rat heart 
ventricles (Fig. 7a). Impaired contractile activity of atria was less 
pronounced (Fig. 7b).  
 
 
Figure 7. Effects of CaR inhibition on isolated heart muscle strips. a. 
CaR inhibition with NPS2390 (100µM) on the heart ventricular strips b. 
NPS2390 (100µM) effect on the atrial heart muscle strips. Contraction 
force was measured in grams. Data are means ± SEM from n=7 strips; 
*p<0.05 vs control. 
5.1.4. Effects of CaR activation on cardiomyocytes function and 
cardiac tissue contractility 
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Other CaR agonists are also able to increase CaR-dependent effect on 
cell shortening. These experiments were performed again on isolated 
cardiomyocytes and heart muscle strips. Isolated cardiomyocytes with 
physiological Ca
2+
-concentration were exposed to polyamine putrescine 
and gadolinium (Gd) incubation at physiological Ca
2+
-concentration.  
Putrescine increased isolated cell shortening by approximately 12%. 
Cells incubated with Gd showed a bit higher increase in shortening 
(approximately 20% comparison to control) (Fig. 8a). In the same time, 
relaxation velocity had tendency to growth under CaR selective 
stimulation (Fig. 8b).  
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Figure 8. Effects of CaR stimulation on the cell function. a. Load free 
cell shortening under CaR stimulation. b. Relaxation velocity of 
cardiomyocytes under CaR stimulation; putrescine (10 µM), Gd (1 mM). 
Data are means ± S from n=36 cells; *p<0.05 vs control values. 
Similar to the experiments performed on isolated cardiomyocytes, CaR 
agonists putrescine and another polyamine spermine, increased 
contraction force on left ventricular heart muscle strips (experiments 
were performed using tesometry equipment) but effects of putrescine 
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was stronger (Fig. 9a, 9b). Same activation was accomplished for atrial 
tissue (Fig. 9c, 9d). Both polyamines had only a minor effect on atria 
tissue.  
 
Figure 9. Effects of CaR activation on heart muscle strips contraction 
force. a. Putrescine effect on ventricular heart muscle strip contractility 
b. Heart ventricular tissue contractility under spermine incubation (initial 
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signals were recorded starting from 10 min after signal got stable) c. 
Effects of putrescine on atrial contraction force d. Spermine effect on 
heart atrial contraction force; Putrescine – 300 µM, Spermine – 300 µM. 
Control values (0 min) were taken as 100%. Data are means ± SEM from 
n=10 stripes; *p<0.05 vs control values in the beginning of stimulation.  
 
5.1.5. Acute effects of putrescine and Gd on the Ca
2+
-transients of 
isolated cardiomyocytes 
To check whether CaR activation leads to changes in systolic and 
diastolic Ca
2+
, Fura-2 AM-loaded isolated cardiomyocytes were exposed 
to putrescine and Gd for 10 min.  Ion optics system, used for these 
purposes, gives a possibility to measure any variations in Ca
2+
-transients. 
Similar to the increased cell shortening, putrescine (Fig. 10a dotted line) 
and Gd (Fig. 10c dotted line) showed an increase in systolic Ca
2+
. This 
effect was observed during first 10 min and then went to plateau phase. 
In the same time, diastolic Ca
2+
 did not show any changes in the 
presence of CaR agonists (Fig. 10a, 10c solid line). Previously obtained 
increase in relaxation velocity correlates to a decreased time of Ca
2+ 
presence in sarcolemma of cardiomyocytes, because the time required 
for the Ca
2+
-uptake back to SR significantly reduced after cells were 
incubated with CaR agonists (Fig. 8b). 
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Figure 10. Ca
2+
-transients under CaR activation. a. Systolic (dotted line) 
and diastolic (solid line) Ca
2+
 load under putrescine stimulation b. Ca
2+
-
uptake to intracellular stores under putrescine; x axis indicating 
experimental time, y axis indicating time required for Ca
2+
-uptake c. 
Effects of Gd on the systolic (dotted line) and diastolic (solid line) Ca
2+
 
d. Ca
2+
-uptake under Gd stimulation; x axis indicating experimental 
time, y axis indicating time required for Ca
2+
-uptake. Putrescine – 10 
µM, Gd – 1 mM. Data are means ± SD from n=36 cells. *p<0.05 vs 
control (0 min). 
5.1.6. Load-free cell shortening under chronic inhibition of CaR 
More convincing evidence of CaR role in basal cell shortening would be 
an effect of downregulated CaR. siRNA directed against CaR (24h) and 
receptor antagonist NPS2390 (24h) were used for these purposes. CaR 
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expression was reduced in cardiomyocytes under NPS2390 and siRNA 
chronic stimulation (Fig. 11a). Similarly to the acute effects (Fig. 11b), 
NPS2390 reduced cell shortening in over-night stimulation. siRNA 
directed against CaR also lowered contractile activity (Fig. 11c).   
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Figure 11. Effects of CaR downregulation a. Representative Western 
Blot indicating CaR protein expression in control and under NPS2390 
(10 µM) and siRNA vs CaR (0.05 µM) 24 h stimulation. b. Load free 
cell shortening of cardiomyocytes after overnight incubation with 
NPS2390 in concentration-dependent manner. c. Effect of NPS2390, 
siRNA vs CaR and scramble (neg.siRNA, 0.05 µM) on cell shortening. 
Data are means ± SD from n=100 cells, *p<0.05 vs control.  
5.1.7. CaR agonists-dependent PKC activation 
CaR activation is supposed to promote PLC-dependent IP3 formation. In 
parallel diacylglycerol (DAG) production takes place and leads to PKC 
activation. PKC in turns phosphorilates phospholamban (PLB) at 
positions 10 and 16 [Shintani-Ishida et al., 2011]. PLB is an established 
PKC target in cardiomyocytes [Simmerman et al., 1986]. Total PKC 
activity was detected in isolated cardiomyocytes incubated with 
putrescine and Gd and compared with untreated controls. Both agonists 
increased PKC activity (Fig. 12a). A Western Blot confirmed PKC 
activation by determining an enhanced phosphorylation of PLB by CaR 
agonists (Fig. 12b). Levels of phosphorylated PLB under putrescine 
increased by approximately 26% comparison to control. Chelerythrine 
chloride (CEC), used to antagonise PKC, cancelled an effect of 
putrescine by reducing phosphorylated PLB level by approximately 13% 
(Fig. 12c).         
57 
  
58 
 
 Figure 12. PKC activity and phospholamban phosphorylation. a. 
Determination of PKC activity and PKC-dependent phosphorylation of 
PLB. Cells were exposed to putrescine (PUT, 10 µM) or Gd (1 mM) for 
20 mins and PKC activity was measured thereafter. b. Representative 
immunoblot indicating phosphorylated PLB (p-PLB) immunoreactivity 
in cardiac myocytes after 20-min putrescine and CEC (10 µM) 
stimulation. p-PLB values were normalized to total PLB levels. c. 
Densitometric analysis of immunoblots. The fraction of p-PLB to total 
PLB after 20 min putrescine and CEC stimulation. Data are means ± 
SEM of n=4 cell preparations, *p<0.05 vs control. 
 
5.1.8. Effects of PKC on the CaR-dependent functional increase 
PKC effects on contractile ability of heart muscle cells were investigated 
with the cell edge detection system. Determination of PKC effect was 
checked by CaR agonist putrescine. Cells were paced at 2 Hz frequency 
and pre-incubated with CEC for 30 min. Putrescine alone led to an 
increased cell shortening and relaxation velocity as it was shown 
previously. But its effect was abolished by PKC inhibitor (Fig. 13a, 
13b). 
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Figure 13.  Effects of PKC inhibitor on CaR-dependent increase in cell 
shortening. a. Load free cell shortening after 20 min of putrescine (PUT, 
10 µM) and CEC (10 µM) incubation. b. Relaxation velocity under 
putrescine and CEC 20 min stimulation. Data are means ± SEM from n= 
36 cells, *p<0.05 vs control. 
5.1.9. CaR and RAMP1 interaction 
RAMP1 is required for trafficking and proper functioning of CaR. So 
RAMP1 is supposed to influence cardiomyocytes function via mediating 
CaR protein activity. To check this hypothesis, rat ventricular 
cardiomyocytes were incubated with siRNA directed against RAMP1 
and load-free cell shortening was analysed thereafter. Putrescine was 
used to activate CaR and to check its responsiveness under 
downregulated RAMP1. CaR agonist increased shortening and 
relaxation velocity of the cells exposed to scramble RNA, but this effect 
was not observed in cells treated with siRNA vs RAMP1 (Fig. 14b, 14c). 
Immunoblot analysis was performed to confirm the lack of the RAMP1 
protein under siRNA vs RAMP1 stimulation (Fig. 14a). RAMP1 
expression was reduced by 37.0±4.8 % (p=0.022) under siRNA vs 
RAMP1 stimulation.  
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Figure 14. Role of RAMP1 in CaR functioning. a. Representative 
immunoblot indicating lack of RAMP1 protein under siRNA vs RAMP1 
24 h treatment. b. Load-free cell shortening under PUT (10 µM), siRNA 
vs RAMP1 (0.05 µM) and scramble RNA (0.05 µM). c. Relaxation 
velocity under PUT (10 µM), siRNA vs RAMP1 (0.05 µM) and 
scramble RNA (0.05 µM). Data are means ± SEM, from n=36, *p<0.05 
vs siRNA. 
CaR protein expression did not change under siRNA vs RAMP1 
stimulation comparison to scramble RNA (Fig. 15a, 15b). 
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Figure 15. Role of RAMP1 in CaR expression. a. Representative 
immunoblot indicating CaR protein expression under siRNA vs RAMP1 
(0.05 µM) and scramble RNA (0.05 µM). b. Quantitative analysis of 
CaR protein expression. Data are means ± SEM, from n= 4 cultures. 
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5.2. CaR and hypertrophy 
To define the role of CaR in hypertrophy in vivo and in vitro 
hypertrophic heart models were investigated.  
5.2.1. Hypertrophy in vivo. Expression of CaR, ET-receptors and 
RAMP1 
As an in vivo hypertrophic model, the rats with NO-deficiency were 
used. After four weeks these rats develop high blood pressure and 
increased left ventricular mass [Schreckenberg et al., 2015]. mRNA 
levels of CaR, RAMP1, ETA, ETB and ECE-1 were analysed in tissue 
samples from these animals. CaR and RAMP1 mRNA was upregulated 
under NO-deficiency (Fig. 16d, 16e). Vasoconstrictor peptide ET-1, 
produced in vascular endothelial cells, endocardial endothelial cells and 
cardiac myocytes with the help of ECE-1, was reported to be increased 
in those rats [Brunner et al., 1995]. As it was mentioned in Introduction, 
ET-1 acts via two main types of the receptors – ETA and ETB [Fareh et 
al., 1996]. Interestingly, enhanced ETB receptors mRNA expression was 
observed (Fig. 16b) in L-NAME treated rats, whereas, ETA and ECE-1 
did not show any changes (Fig. 16a, 16c). 
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Figure 16. CaR and ET-receptor levels under NO-deficiency in vivo. a. 
ETA; b. ETB; c. ECE; d. CaR; e. receptor RAMP1 mRNA levels after 1 
and 6 months L-NAME treatment. Amplification of cDNA is normalized 
to HPRT. Data are means ± SD from n=8 rats, *p<0.05. 
 
5.2.2. Hypertrophy in vitro. Role of ET-1 and phenylephrine in CaR-
dependent cardiomyocytes shortening  
 
To develop hypertrophy in vitro hypertrophic stimuli such as β-
adrenergic stimulator phenylephrine (PE) and peptide ET-1 were used. 
PE and ET-1 in chronic stimulation both decreased cell shortening and 
relaxation velocity but the effect of ET-1 was potentiated by CaR 
inhibitor NPS2390 (Fig. 17a, 17b). PE effect did not show difference 
under NPS2390 stimulation. 
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Figure 17. Effects of CaR inhibition on cellular function during 
hypertrophy development in vitro.  a. Load free cell shortening under 
ET-1 (100 nM), PE (10 µM) and CaR inhibitor NPS2390 (10 µM) 24 h 
stimulation. b. Relaxation velocity of cardiac myocytes under ET-1 (100 
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nM), PE (10 µM) and CaR inhibitor NPS2390 (10 µM) 24 h stimulation. 
Data are means ± SEM from n=72, *p<0.05 vs control. 
It should be noted, that CaR protein and also mRNA levels were 
significantly higher under ET-1 chronic stimulation (Fig. 18). In the 
same time PE did not led to CaR protein levels elevation (Fig. 19). 
 
 
Figure 18. ET-1-dependent CaR upregulation. a. Representative 
immunoblot indicating CaR protein level under ET-1 (100 nM) 24h 
stimulation. b. CaR protein level under ET-1 (100 nM), 24 h stimulation. 
c. CaR mRNA expression under ET-1 (100 nM), 6h stimulation. p<0.05 
vs controls indicate significance.   
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Figure 19. CaR protein expression during PE-induced hypertrophy 
development. a. Representative Western Blot of CaR protein levels 
under PE concentration-dependent 24 h stimulation b. CaR protein 
expression under PE (0.1 µM, 1 µM and 10 µM) 24 h stimulation. Data 
are means ± SD from n=2 cell preparations. 
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To make the effect of CaR inhibition on load free cell shortening under 
ET-1 more specific, experiments with silenced CaR with siRNA were 
performed. As it was observed previously, inhibition of the receptors 
intensified effect of ET-1 (Fig. 20). 
 
Figure 20. ET-1 effects on cell shortening under downregulated CaR 
expression. a. Load-free cell shortening under ET-1 (100 nM) and 
siRNA vs CaR (0.05 µM) chronic stimulation. b. Relaxation velocity 
under ET-1 and siRNA vs CaR 24h incubation. Data are means ± SD 
from n=72. *p<0.05 vs untreated controls. 
 
5.2.3. ET-1-dependent cardiac remodelling 
ET-1 as pro-hypertrophic stimuli contributes to ventricular remodelling 
[Arai et al., 1995; Sakai et al., 1995].  
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ET-1 in vitro increased cell width and volume, whereas cell length was 
not affected (Fig. 19). CaR inhibitor NPS2390 did not influence ET-1 
remodelling effect. Thus, ET-1 action on cardiomyocytes remodelling is 
CaR-independent.   
 
Figure 21. ET-1-induced hypertrophy development in vitro. a. Cell 
length under 24 h stimulation with ET-1 (100 nM) and NPS2390 (10 
µM) incubation. b. Cell width under ET-1 and NPS2390 24 h 
stimulation. c. Cell volume under ET-1 and NPS2390 over-night 
incubation d. Representative pictures of cardiomyocytes under ET-1 and 
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NPS2390 stimulation (bar on the pictures equals to 100 µm). Data are 
means ± SD from n=2 rats, *p<0.05 vs control. 
 
5.2.4. Effects of different types of ET-receptors on cardiomyocytes 
shortening and CaR expression  
As mentioned above, ET-1 action is mediated via ETA and ETB receptors 
[Fareh et al., 1996]. Both of them presented in heart tissue as well as in 
isolated ventricular cardiomyocytes (Fig. 22). As already indicated there 
are two splice variants of ETB receptors in the heart. They differ 
according to the sensitivity to PD142893. ETB1 are PD142893 sensitive 
and ETB2 are PD142893 resistant. As PD142893 is not specific for ETB1 
it also antagonizes ETA receptors. Cells were exposed to ET-1 and 
PD142893 for 24 h in this study. Load-free cell shortening and 
relaxation velocity were measured. Protein analysis was performed to 
indicate CaR levels under blocked ETB1 and ETA receptors.  
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Figure 22. ET-receptors expression in cardiomyocytes and non-
myocytes. Data are means ± SD from n=4 rats, normalized to ETA 
receptor expression in cardiomyocytes and non-myocytes respectively. 
 
 
Figure 23. Role of ETB receptor subtypes in ET-1-dependent 
modification of cell shortening. a. Load-free cell shortening under ET-1 
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(100 nM) and PD142893 (100 nM) chronic (24 h) stimulation. b. 
Relaxation velocity under ET-1 (100 nM) and PD142893 (100 nM) 
chronic (24 h) stimulation. Data means ± SD from at least 36-72 cells, 
*p<0.05 vs control values. 
Cell shortening was slightly decreased under ET-1, but its effect was 
much stronger under ETB1 and ETA receptors inhibition (Fig. 23a). 
Stronger decrease in relaxation velocity was also observed under 
PD142893 and ET-1 cooperative stimulation comparison to ET-1 alone 
(Fig 23b).  
ET-1 again increased CaR protein levels. This effect was abolished by 
PD142893 (Fig. 24).  
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Figure 24. Role of ETB receptors subtypes in ET-1-dependent up-
regulation of CaR a. Representative immunoblot; b. Quantitative 
analysis of the expression. Cells were incubated with ET-1 (100 nM) 
and/or PD142893 (100 nM) for 24 h. Data means ± SD from n=4 
cultures and normalized to ET-1 induced values, *p<0.05. 
 
To confirm that the negative effect of ET-1 on cell shortening is 
PD142893-dependent, a second ETB-receptor-specific inhibitor was 
used. (Fig. 25).  ET-1 together with PD142893 significantly decreased 
shortening (Fig. 25a) and relaxation velocity (Fig. 25b) of 
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cardiomyocytes, whereas this effect was blocked by ETB receptors 
inhibitor (BQ788).  
 
Figure 25. Load-free cell shortening under ETA/ETB receptors 
inhibition a. Load free cell shortening; b. Relaxation velocity of 
cardiomyocytes. Cells were exposed to ET-1 (100 nM), PD142893 (100 
nM) and BQ788 (100 nM) for 24. Data are means ± SD from n=72 cells, 
*p<0.05. 
 
5.2.5. Effect of PD142893 on a hypertrophic remodeling of cardiac 
myocytes 
Finally, we investigated the effect of PD142893 on cardiac hypertrophy. 
Inhibition of ETA/ETB1 completely attenuated the concentration-
dependent increase in cell width and volume (Fig. 23). 
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Figure 26. Role of ETA,B1 receptor subtypes in ET-1-dependent 
hypertrophy. a.-c. Cells length, width, and volume of cardiomyocytes 
cultured with ET-1 (100 nM) and PD142893 (100 nM) during 24 h. Data 
are means from at least 59 cells, *p<0.05 vs. untreated controls. 
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6. Discussion 
6.1. CaR involvement in heart contractility  
The CaR are presented throughout the entire cardiovascular system: in 
the cardiac muscle and blood vessels. Its activation leads to different 
intracellular signaling cascades and various biological reactions. They 
are supposed to participate in the heart cells contractility and relaxation 
[Schreckenberg et al., 2015]. Furthermore, they take part in blood 
pressure modulation [Weston et al., 2005], influence protein expression, 
and they are involved in I/R injury and apoptosis [Zhen et al., 2016]. The 
nature of the intracellular pathway, activated by CaR, depends markedly 
on the cell type in which the receptors are expressed.  
In 2003 Wang et al. demonstrated the presence of CaR in the 
cardiomyocytes that were isolated from Sprague–Dawley rats. Since 
then further investigations of CaR in the cardiovascular system have 
been performed. The mRNA of CaR was detected in both - atrial and 
ventricular cardiomyocytes. In the heart cells the receptors are known to 
be connected to Gαq proteins leading to the PLC and MAPK pathways 
activation [Tfelt-Hansen et al., 2005; Tfelt-Hansen et al., 2006].      
In our study we confirmed that isolated adult cardiomyocytes of Wistar 
rats express CaR under physiological conditions and that the receptors 
contribute to the basal electromechanical coupling. 
We were able to detect differences in CaR expression between atrial and 
ventricular tissue. The nature of this expression differences is not clear 
yet, but probably it is due to the crucial pumping role of ventricles which 
is not present in atria. 
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CaR are mainly activated by Ca
2+
 ions [Hofer et al., 2003]. However, as 
a crucial molecule in the heart, it also influences cell contractility in 
CaR-independent way. To distinguish the effect of CaR and Ca
2+
 ions 
themselves, load-free cell shortening under CaR inhibition and under 
different extracellular Ca
2+
-concentration was measured. The highest 
activity of the receptors was detected under almost physiological Ca
2+
-
concentration (1-1.25 mM). 
To study an effect of CaR activation on heart muscle strips and isolated 
heart muscle cells, positive charged synthetic molecule Gd, petrescine 
and spermine were used.  
Putrescine and spermine are natural polyamines, highly positive-charged 
molecules, occurring in all living cells. Together with Ca
2+
 ions they 
belong to the group of natural direct agonists of CaR. Polyamine 
putrescine is produced from amino acid ornithine under the activity of 
the ornithine decarboxylase (ODC). The product of ODC, is then 
converted to spermine under activity of specific aminopropyl-transferase 
spermine synthase. Polyamine formation is induced by several growth 
and differentiation stimuli. Interestingly, they are essential for cell 
proliferation [Oreddsson et al., 2003] and play a role in the development 
of heart muscle hypertrophy [Caldarera et al., 1971; Bartolome et al., 
1980; Pegg et al., 1980]. An increase in polyamine concentration was 
detected in heart tissue after ascending aortic stenosis [Feldman et al., 
1972], stress [Russell et al., 1971], administration of adrenoceptor 
agonists [Warnica et al., 1975; Cubria et al., 1998; Schlüter et al., 2000] 
and physical exercise [Caldarera et al., 1974;  Retting et al., 1977] – all 
precursors of cardiac hypertrophy. Increased polyamine levels were 
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associated with elevated RNA and protein synthesis [Moruzzi et al., 
1974, Gibson et al., 1974].                                                                                                    
Challenging isolated ventricular cardiomyocytes with polyamines led to 
an increased contraction force of heart muscle strips. Load free cell 
shortening was also higher with CaR agonists. At the same time, 
increased relaxation velocity of cardiac myocytes was observed.  Same 
agonists induced concentration-dependent Ca
2+
-increase inside the cell. 
Tfelt-Hansen et al. previously explained increased intracellular Ca
2+
 by 
IP3 elevation within the cell, thus suggesting the link of the receptor to 
PLC/IP3 pathway [Tfelt-Hansen et al., 2006].  
Ca
2+
-decay was also faster comparison to control values, which 
corresponds with higher relaxation velocity observed in beating cells 
under CaR activation. Along with increased IP3 formation, there is 
parallel enhanced DAG synthesis (Fig. 27). DAG and Ca
2+
 ions are 
required for the PKC activation. PKC in turns phosphorylates protein 
PLB at the positions 10 and 16 [Colyer et al., 1998]. The increased 
activity of PKC and increased phosphorylated PLB levels were observed 
in present study. Phosphorylated form of PLB is increasing 
sarco/endoplasmic reticulum Ca
2+
-ATPase (SERCA) activity. 
Phosphorylated PLB separates from SERCA, and SERCA, in turns, has 
higher potency of Ca
2+
-uptake. Enhanced Ca
2+
-uptake indicates 
increased relaxation velocity.  
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Figure 27. CaR-mediated intracellular signaling pathway in cardiac 
myocytes [Modified from Sergio et al, 2003]. 
 
To determine the role of CaR in the basal cell shortening CaR’s non-
specific negative allosteric modulator NPS2390 and siRNA vs CaR were 
applied. They significantly decreased cellular function by approximately 
15% in acute and chronic ways. Western Blot confirmed the lack of the 
receptor protein under siRNA vs CaR and NPS2390 chronic inhibition. 
NPS2390 also decreased contraction force of isolated heart muscle strips 
in time-dependent manner.  
The CaR belong to the large group of GPCRs and as other receptors 
from this group require RAMPs for the trafficking, function and 
appropriate localization [Parameswaran et al., 2006]. These single-
transmembrane proteins expressed in many tissues and cells [McLatchie 
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et al., 1998; Morfis et al., 2003]. Class and individual isoform of these 
proteins depend on the cell and tissue type where they are shown to be 
expressed [Parameswaran et al., 2006]. Three types of these proteins are 
identified: RAMP1, RAMP2 and RAMP3. RAMP1 was isolated from 
human as a receptor for functioning and trafficking of the calcitonin 
gene-related peptide (CGRP) in 1998. RAMP2 and RAMP3 were 
detected later on by database searching [McLatchie et al., 1998]. 
Although, proteins were shown mostly to mediate activity of class B 
GPCRs, recently class C was also identified as receptors requiring 
RAMPs activity.    
RAMP1 and RAMP3 association with CaR expressed on the cell surface 
in COS7 was observed [Bouschet et al., 2005]. Another study performed 
on HEK293 cells showed alteration in CaR trafficking under 
downregulated RAMP1 [Bouschet et al., 2005]. RAMPs promote 
trafficking of the CaR from endoplasmic reticulum to the Golgi 
apparatus and mediate the terminal glycosylation of the receptor.  
Cardiac cells with downregulated RAMP1 had impaired respond to the 
CaR agonist putrescine in current study. However, immunoblot analysis 
did not detect any differences in CaR protein expression between control 
cells and cells with silenced RAMP1. This suggests that RAMP1 
deficiency is not responsible for the lack of CaR protein in 
cardiomyocytes in general, but leads to its absence on the cell surface. 
So far we can make intermediate conclusion about the role of the CaR in 
cardiomyocytes expression and functioning. Our study showed the 
presence of the receptor in cardiomyocytes derived from Wistar rats and 
that these receptors significantly contribute to the basal cell shortening. 
Mechanism of this contribution involves the PLC and the PKC 
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activation, leading to an increased intracellular Ca
2+
-release and Ca
2+
-
uptake with subsequent increase in cells shortening and relaxation. It 
should be noted, that CaR are efficient to increase cellular shortening at 
nearly physiological Ca
2+
-concentrations. In addition, for the cell surface 
expression and proper function CaR require the activity of RAMP1.  
 
6.2 Role of CaR in the heart functioning during hypertrophy 
development 
The presence of the receptor was also shown in blood vessels of different 
species. The CaR protein was detected in perivascular nerves in rat 
mesenteric, renal, coronary and vertebral arteries [Bukoski et al., 1997; 
Wang et al., 1998; Ruat et al., 1995]. For instance, activated vascular 
endothelial CaR open Ca
2+
-sensitive potassium channels by inducing 
subsequent hyperpolarization [Weston et al., 2005]. CaR expressed in 
perivascular sensory nerves of arteries mediates Ca
2+
-induced relaxation 
[Bukoski et al., 1997].  A functional CaR protein has been reported in 
endothelial cells from rat mesenteric and porcine coronary arteries 
[Weston et al., 2005]. Other group reported the presence of the CaR in 
endothelial cells of human aorta where it modulates NO production 
[Ziegelstein et al., 2006]. These studies indicate the role of the receptor 
in blood pressure modulation by inducing hyperpolarization and NO 
synthesis.   
They are also supposed to play a role during development of different 
heart disease. For example, CaR are involved in pulmonary vascular 
remodeling and pulmonary hypertension [Yamamura et al., 2012; Peng 
et al., 2014], I/R injury and heart failure development [Yan et al., 2011]. 
Interestingly, CaR protein levels were increased under Ang-II 
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stimulation, pointing to the CaR involvement in hypertrophy [Wang et 
al., 2008]. There is also upcoming evidence of CaR participation in post-
ischemic heart recovery and heart failure progression [Gan et al., 2012; 
Lu et al., 2013]. Thereby, the CaR seem to be an active player on the cell 
surface of the cardiovascular system also participating in its functioning 
during heart diseases development and progression. 
Hypertension takes a big part among risk factors leading to death later 
on. High blood pressure affects between 16 and 37 % of the global 
population [Poulter et al., 2015]. In 2010, hypertension was assessed as 
17.8% of premature deaths (9.4 million) and 7% of disability worldwide 
[Campbell et al., 2015]. Thus, hypertension and developed later on 
hypertrophy are one of the most important targets of investigation. So far 
expression of CaR in chronic hypertension was not clearly tested.      
As it was indicated above, in vivo and in vitro hypertrophic models were 
used to assess the involvement of CaR into the hypertrophy progression. 
Hypertrophy in vitro was evoked by use of the commonly known 
hypertrophic stimuli - ET-1 and PE [Hinrichs et al., 2011]. 
An in vivo model is the hypertensive rat model with NO-deficiency. This 
part of the study was used here as a hypothesis generating part. We 
hypothesized that chronic NO-deficiency, which also leads to 
hypertrophy development, increases the cardiac expression of RAMP-1 
and CaSR and that ET-1 triggers this effect. NO deficiency is usually 
associated with endothelial dysfunction in cardiovascular system under 
stress conditions [Cai et al., 2000]. As a strong vasoconstrictor ET-1 
antagonizes the activity of NO in smooth muscle cells and 
cardiomyocytes. NO reduces ET-1 secretion thus removing ET-1 effect 
in the heart while rats with developed NO-deficiency show increased 
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ET-1 release [Brunner et al., 1995]. It should be also noted that NO can 
reduce polyamine levels, one of the main CaR agonists, and inhibit ODC 
activity [Bauer et al., 1999] and vice versa, polyamines can inhibit NO 
synthesis by reducing NOS activity [Hu et al., 1994]. Increased CaR and 
RAMP1 mRNA levels were observed in rats under NO-deficiency, 
which confirms correlation between these two proteins.  
In vitro ET-1 and PE chronic stimulation led to drop of load free cell 
shortening and relaxation velocity. NPS2390, used to antagonize the 
CaR, enhanced the ET-1 effect, but not the effect of PE. Similar results 
were obtained under silenced CaR and ET-1 stimulation. ET-1 again 
slightly decreased cell shortening, but its effect was much stronger under 
downregulated CaR.  Following question was addressed: Did chronic 
ET-1 stimulation and CaR inhibition enhance functional drop together in 
independent manner or there is an interaction between these receptors 
pathways? 
Protein analysis did not show changes in CaR expression under PE 
stimulation. However, increased CaR levels were observed under ET-1 
(after 24 h), suggesting that CaR can partly compensate loss of cellular 
function under ET-1-dependent hypertrophy development. Nevertheless, 
mechanisms of this upregulation remain elusive.  
ET-1 effect in the heart is implemented via GPCRs and mediates IP3-
dependent Ca
2+
-release in acute stimulation. Chronic stimulation shows 
the opposite effect. The type of ET-receptors, responsible for the cardiac 
remodeling and the inhibited function of the heart cells, is not known. 
Enhanced ETB receptors mRNA was observed in experimental rat model 
with NO-deficiency, whereas ETA and ECE did not show any changes. 
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Previously mentioned, that ET-1 in long-term exposure leads to cardiac 
hypertrophy development. Likely, this effect is provided mainly by ETB 
receptors type [Lee et al., 2004]. To check which ET receptor type is 
responsible for the CaR upregulation, different ET-receptor antagonists 
were used. ETB receptors are expressed in two different splice variants. 
The functional importance of the two variants was investigated by 
pharmacological approaches using PD142893. The inhibitor blocks the 
activation of ETA and ETB1 receptors, respectively, leaving ETB2 receptor 
signalling intact. Stimulation of cardiomyocytes with PD142893, 
revealed differences in CaR expression. ET-1 in chronic way increased 
CaR expression as it was reported in previous experiments, whereas 
PD142893 abolished this effect. PD142893 potentiated ET-1-dependent 
loss of the cell function. Specificity of PD142893 was checked by ETB 
receptor blocker, which together with PD142893 completely attenuated 
depressive effect of ET-1. This suggests that likely, receptors remaining 
unblocked under PD142893 are ETB. Moreover, increased cell volume 
under ET-1 was not observed during PD142893 application. Apparently, 
ET-1 long-term application via ETA or ETB1 induce hypertrophic 
cardiomyocytes remodelling and CaR upregulation.  
Second conclusion indicating the role of CaR in hypertrophy 
development could be done. It is supposed that ET-1 in chronic 
stimulation via ETA or ETB1 receptors not only leads to cardiomyocytes 
remodelling and attenuates their function, but also upregulates CaR 
expression. CaR upregulation is supposed to compensate loss of 
contractile function of cardiac myocytes during hypertrophy 
development. The data are summarized in Fig. 28   
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Figure 28. Schematic summary of the data obtained in this study. ET-1 
acts on three different populations of ET-receptors (ETA, ETB1) and 
ETB2. While ETB2 receptor activation (ET-1 in presence of PD142893) 
induces a loss of cell function (reduced load-free cell shortening), 
activation of ETA and ETB1 receptors up-regulate CaR that stabilizes cell 
function. The latter effect requires RAMP-1. 
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7. Conclusion 
In conclusion, our study shows that CaR are involved in physiological 
Ca
2+
-handling of adult rat ventricular cardiomyocytes and contribute 
approximately 15% to basal electromechanical coupling of 
cardiomyocytes. To be functionally expressed on the cardiomyocytes 
surface CaR require activity of RAMP1. Furthermore, it revealed that 
up-regulation of CaR, as it occurs in ET-1-dependent hypertension via 
ETA or ETB1 receptors stimulation, stabilizes cardiac function. 
Pharmacologically, selective inhibition of ETB1 or ETA receptors may 
delay the transition of compensatory hypertrophy to heart failure.  
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9. Summary 
Background. Ca
2+
 is commonly known as a crucial molecule in heart 
tissue. It triggers signal transduction, cellular contractility, and activates 
enzymes. Moreover, Ca
2+
 is considered to be an important second 
messenger in cardiovascular tissue. Recently, Ca
2+
 ions were shown to 
act as a first extracellular messengers via special calcium-sensing 
receptors (CaR). These receptors are G protein-coupled and are present 
in many organs and tissues throughout the entire body including the 
cardiovascular system. They are supposed to activate several signaling 
cascades in cardiomyocytes. In the past few years, the involvement of 
CaR in heart diseases was shown in many publications. CaR are 
involved in ischemia-reperfusion injury, hypertension, hypertrophy and 
heart failure development. However, underlying mechanisms remained 
elusive so far. Thus in present study we aimed to investigate on the role 
of CaR in physiological heart function and during the development of 
cardiac hypertrophy. 
Materials and Methods. Experiments were performed on isolated 
cardiomyocytes and heart muscle strips. Load-free cell shortening was 
measured with a special cell-edge detection system.  Contraction force of 
the heart muscle strips was measured using tensometry equipment. Cells 
and tissue material were exposed to Western Blot and RT-PCR analysis. 
Ca
2+
-transients were detected in isolated cardiac myocytes loaded with 
FURA-2AM by ION Optix system. To determine protein kinase C 
(PKC) activity under CaR stimulation, special nonradioactive PKC 
activity assay was used. Hypertrophy was modulated in vivo and in vitro. 
As in vivo model rats with NO-deficiency were used. Hypertrophy in 
vitro was provoked by adding ET-1 and PE to the cardiomyocytes 
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culture for 24 h. Polyamines putrescine and spermine and synthetic CaR 
agonist gadolinium (Gd) were used to activate CaR and NPS2390 and 
siRNA vs CaR to antagonize the receptor. 
Results. CaR in physiological heart function. RT-PCR and Western 
Blot analysis confirmed the presence of the receptor in adult rat 
cardiomyocytes. Differences in CaR expression between right and left 
ventricular and atrial tissues were detected. Cells and heart muscle strips 
shortening as well as relaxation velocity of cardiomyocytes increased 
under CaR activation. Inhibition of the receptor lead to a reduced 
contraction force of the heart strips and decreased load-free cell 
shortening of cardiomyocytes, and also to a deceleration of the 
relaxation velocity. Significant effect of CaR inhibition was observed 
just under physiological Ca
2+
-concentrations. The effect of CaR agonists 
and inhibitors on atrial strips was less pronounced. Systolic Ca
2+
 and 
Ca
2+
-uptake to the sarcoplasmic reticulum (SR) were enhanced under 
CaR activation. Putrescine increased the activity of PKC and the levels 
of phosphorylated phospholamban (PLB). Moreover, inhibition of PKC 
abolished the effect of CaR activation on load-free cell shortening and 
relaxation velocity of cardiomyocytes. Effect of CaR was also abolished 
under downregulated RAMP1.  
CaR and hypertrophy. Hypertrophy developed in vivo was 
accompanied by increased mRNA levels of CaR and RAMP1. 
Interestingly, the mRNA of ETB receptors was also enhanced in one 
month L-NAME treated rats, whereas ETA and ECE showed no 
differences. 
ET-1 and PE chronic stimulation decreased shortening and relaxation 
velocity of the cells. However, the effect of ET-1 was potentiated by 
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NPS2390 and siRNA vs CaR. Enhanced CaR protein expression was 
shown under ET-1 exposure for 24 hours, but not under PE stimulation. 
Inhibition of ETB1 and ETA receptors cancelled ET-1 remodeling effect 
and enhanced CaR protein expression.  
Conclusion. Cardiomyocytes express CaR under physiological 
conditions and this contributes to the basal electromechanical coupling 
of cardiomyocytes under nearly physiological Ca
2+
concentrations. 
Activation of the receptor with direct agonists is able to further increase 
contractility. It is also leading to the enhanced relaxation velocity which 
is explained by PKC activation, PLB phosphorylation and enhanced 
SERCA activity. To be functionally expressed on cardiomyocytes’ 
membrane, CaR require the activity of RAMP1. 
During the development of pressure induced hypertrophy, ET-1 via ETA 
or ETB1 receptors is able to upregulate CaR expression. Elevated levels 
of CaR are supposed to compensate a loss of the heart function during 
hypertrophy development. 
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10. Zusammenfassung: 
 
Hintergrund: Ca
2+
 ist ein wichtiges Molekül für die kardiale Funktion. 
Es triggert Signaltransduktion, Kontraktilität und aktiviert Enzyme. Ca
2+
 
kann als wichtiger sekundärer Transmitter betrachtet werden. Allerdings 
wirkt Ca
2+
 auch als erster Signalbotenstoff durch Bindung an den 
Calcium-Sensing-Rezeptor (CaR). CaR sind G-Protein gekoppelte 
Rezeptoren, die sich in vielen Organen des Körpers finden. CaR sind an 
der Entstehung von Reperfusionsschäden, Hypertension, Hypertrophie 
und Herzinsuffizienz beteiligt. Die zugrunde liegenden Mechanismen 
sind weniger klar und Gegenstand dieser Untersuchungen. 
Material und Methoden: Funktionelle Untersuchungen wurden an 
isolierten Kardiomyozyten und Muskelstreifenpräparaten durchgeführt. 
Die lastfreie Zellverkürzung isolierten Herzmuskelzellen wurde mit 
Hilfe eines Zellendendetektionssystems bestimmt. Zell- und 
Gewebeanalysen wurden auch mittels Western Blot und RT-PCR 
Technik durchgeführt. Calcium-Transienten wurden unter FURA-2AM 
Beladung der Zellen bestimmt. Proteinkinase C Aktivität wurde mittels 
nicht-radioaktiven Detektionssystemen (ELISA) bestimmt. Als in vivo-
Modell der kardialen Druckbelastung wurden Ratten mit NO-Defizienz 
untersucht. Zelluläre Hypertrophie wurde durch Zugabe von 
Phenylephrin und Endothelin ausgelöst. CaR Stimulation erfolgte durch 
Putrescin und Gadolinium.  
Ergebnisse: CaR unter physiologischen Bedingungen: RT-PCR und 
Western-Blot Analysen bestätigten eine konstitutive Expression des CaR 
in adulten Rattenkardiomyozyten. Die stärkste Expression fand sich im 
linken Ventrikel. CaR Aktivierung führte zur Zunahme der Verkürzung 
und Relaxationsgeschwindigkeit von Kardiomyozyten und 
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Muskelstreifen. Am stärksten beeinflusste CaR-Stimulation die 
Zellverkürzung bei nahezu physiologischer Ca
2+
-Konzentration. Effekte 
durch Stimulation des CaR waren am Vorhof weniger ausgeprägt. Die 
Ca
2+
-Transienten waren unter Stimulation des CaR verbessert. 
Putrescine aktivierte die Proteinkinase C und bei Hemmung der 
Proteinkinase C waren die positiv inotropen Wirkungen der CaR-
Stimulation unterdrückt. 
CaR und Hypertrophie: In dem hier verwendeten Hypertrophie-Modell 
kam es in vivo zu einer verstärkten Expression von CaR und RAMP1. 
Interessanterweise nahm auch die Expression des ETB Rezeptors zu. 
Langfristig führte eine Exposition der Zellen mit ET-1 zu einer 
Abnahme der lastfreien Zellverkürzung, aber der Effekt war viel 
ausgeprägter unter Hemmung des CaR oder nach Herabregulation des 
Rezeptors. Pharmakologische Experimente zeigen, dass eine Stimulation 
der ETA- oder ETB1-Rezeptoren die negativen Effekte von Endothelin-1 
durch Induktion des CaR begrenzen. 
Schlussfolgerung: Kardiomyozyten exprimieren konstitutiv einen CaR 
der zur basalen Zellverkürzung beiträgt. Eine Aktivierung des CaR führt 
zur Verstärkung der Zellverkürzung, durch Proteinkinase C-abhängige 
Phosphorylaierung von Phospholamban und nachfolgender 
Verbesserung der Ca
2+
-Transienten. Kardiomyozyten benötigen RAMP1 
zur Verankerung des Rezeptors an der sarkolemmalen Membran. Bei 
prohypertropher Stimulation mit Endothelin-1 kann eine 
Heraufregualtion des CaR zur partiellen Kompensation eines 
hypertrophie-bedingten Funktionsverlustes beitragen. 
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